Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

Blood (2024) 144 (Supplement 1): 6199.

https://doi.org/10.1182/blood-2024-204481

Published: 2024

Journal Articles

High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings

Zafar Iqbal, PhD, Afia Muhammad Akram, Tanveer Akhtar, PhD, Muhammad Khalid, MPhil PhD, Zeba Aziz, MD MBBS, Aamer Aleem, MBBS FRCP, Ammara T Gill, MBBS ABIM, Ahmad M Khalid, PhD, Abdullah Alanazi, MBBS, Ijaz H Shah, MD, Muhammad Khalid, MBBS, MPhil, Muhammad Farooq Sabar, PhD, Mudassar Iqbal

Blood (2015) 126 (23): 5167.

https://doi.org/10.1182/blood.V126.23.5167.5167

Published: 2015

Journal Articles

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Blood (2014) 124 (21): 1810.

https://doi.org/10.1182/blood.V124.21.1810.1810

Published: 2014

Journal Articles

Detection of Five Common Fusion Oncogenes in Pakistani Children with Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and Treatment Outcome

Blood (2012) 120 (21): 5124.

https://doi.org/10.1182/blood.V120.21.5124.5124

Published: 2012

Journal Articles

Characterization of Common Fusion Oncogenes As Prognostic Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need for Genetic Testing At Presentation, Molecular Prognostication and Differential Treatment

Blood (2012) 120 (21): 5115.

https://doi.org/10.1182/blood.V120.21.5115.5115

Published: 2012

Journal Articles

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Zafar Iqbal, BSc, MSc, MPhil, PhD, Mudassar Iqbal, MD, Tanveer Akhtar, MSc, PhD, Mubashar Iqbal Naqvi, BS(CS), Ammara H Tahir, MBBS, Tariq Jameel Gill, MBBS, Muhammad Naeem Abbas, MLT, Abid Jamil, MBBS, PhD, Abid Sohail Taj, MBBS, PhD, Dr Abd-Al-Qayyum, MD, Najeeb ur-Rehman, BS, (Engg), Muhammad Ferhan, MSc, MPhil, Ijaz Hussain Shah, MBBS, FCPS, Muhammad Khalid, MBBS, FCPS, Weng Xian Qin, BSc(MLT), MS, Ahmad Mukhtar Khalid, MSc, PhD, Mahwish Khan, Aamer Aleem, MD, Shahid Mahmood Baig, MPhil, PhD

Blood (2010) 116 (21): 2278.

https://doi.org/10.1182/blood.V116.21.2278.2278

Published: 2010

NARROW

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Detection of Five Common Fusion Oncogenes in Pakistani Children with Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and Treatment Outcome

Characterization of Common Fusion Oncogenes As Prognostic Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need for Genetic Testing At Presentation, Molecular Prognostication and Differential Treatment

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Email alerts

ASH Publications

American Society of Hematology

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings

Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol

Detection of Five Common Fusion Oncogenes in Pakistani Children with Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and Treatment Outcome

Characterization of Common Fusion Oncogenes As Prognostic Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need for Genetic Testing At Presentation, Molecular Prognostication and Differential Treatment

Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only